Combination therapy with anti-TYRP1 / anti-CD3 bispecific antibody and TYRP1-specific antibody
The combination of anti-TYRP1/anti-CD3 dual antibodies with a TYRP1-specific antibody addresses the limitations of current cancer treatments by enhancing tumor targeting and survival rates through simultaneous TYRP1 and CD3 engagement, achieving improved therapeutic outcomes.
Patent Information
- Application Number
- JP2024531258
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-26
- Filing Date
- 2022-11-25
- Publication Date
- 2024-11-20
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current cancer treatments, particularly those targeting TYRP1 and CD3, fail to induce long-term responses and cures, necessitating the development of new compounds and combinations that can significantly enhance patient survival rates without unacceptable toxicity.
A combination therapy using anti-TYRP1/anti-CD3 dual antibodies, comprising specific heavy and light chain variable domains, in combination with a second TYRP1-specific antibody, to target TYRP1 and CD3 simultaneously, enhancing cytotoxic T cell activation and tumor cell lysis.
The combination therapy demonstrates superior median and overall survival in cancer models by effectively targeting TYRP1-expressing tumors, including improved survival rates compared to single-agent treatments.
Smart Images

Figure 2024543257000008 
Figure 2024543257000001 
Figure 2024543257000002
Abstract
Description
[Technical field]
[0001] The present invention relates to bispecific antibodies that bind to human TYRP1 and CD3, and to combination therapies of TYRP1-specific antibodies. [Background technology]
[0002] Cancer is the number one cause of death in developed countries and the second leading cause of death in developing countries. Despite recent advances in chemotherapy, as well as the development of drugs targeted at interfering with the transmission and regulation of growth signals in cancer cells at the molecular level, the prognosis of patients with advanced cancer generally remains poor. As a result, there is a persistent and urgent medical need to develop new therapies that can be added to existing therapies to increase survival rates without causing unacceptable toxicity.
[0003] CD3 (cluster of differentiation 3) is a protein complex composed of four subunits, the CD3γ chain, the CD3δ chain, and two CD3ε chains. CD3 associates with the T cell receptor and the ζ chain to provide activation signals in T lymphocytes. CD3 has been widely studied as a drug target. Monoclonal antibodies targeting CD3 have been used as immunosuppressive therapy in the treatment of autoimmune diseases such as type I diabetes or graft rejection. The CD3 antibody muromonab-CD3 (OKT3) was the first monoclonal antibody approved for clinical use in humans in 1985.
[0004] Recent applications of CD3 antibodies take the form of bispecific antibodies that bind CD3 on the one hand and tumor cell antigens on the other (Clynes and Desjarlais (2019) Annu. Rev. Med. 70:437-50). Simultaneous binding of such antibodies to both targets results in a transient interaction between the target cell and T cells, leading to the activation of cytotoxic T cells and subsequent lysis of the target cell. For this purpose, bispecific antibodies that bind CD3 and the tumor cell antigen TYRP1 have been developed and are described, for example, in WO 2020 / 127619. TYRP1 as a target is present in melanoma cells and in melanocytes involved in melanin synthesis and also affects melanocyte proliferation and survival in humans. TYRP1 antibodies have been previously described (Boross et al., (2014) Immunol Lett. 160(2):151-7) and have been tested in clinical trials (Khalil et al., (2016) Clin Cancer Res. 22(21):5204-5210). For use in mouse models, TYRP1 and T cell bispecific surrogate antibodies have been described that mediated antitumor efficacy but failed to induce long-term responses / cures (Benonisson et al. (2019) Mol Cancer Ther. (2):312-322; Labrijn et al. (2017) Sci Rep. 7(1):2476).
[0005] There remains a need for new compounds and combinations that have the potential to significantly contribute to patient treatment. Accordingly, we herein describe novel combination therapies with TYRP1 antibodies and bispecific antibodies that bind TYRP1 and CD3. Summary of the Invention
[0006] The present invention includes an anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1-specific antibody for use as combination therapy in the treatment of cancer, for use as combination therapy in the prevention or treatment of metastasis, wherein the anti-TYRP1 / anti-CD3 bispecific antibody comprises a first antigen-binding portion that specifically binds TYRP1 comprising a heavy chain variable domain VH of SEQ ID NO: 1 and a light chain variable domain VL of SEQ ID NO: 2, and a second antigen-binding portion that specifically binds CD3 comprising a heavy chain variable domain VH of SEQ ID NO: 3 and a light chain variable domain VL of SEQ ID NO: 4, wherein the second TYRP1-specific antibody comprises an antigen-binding portion that specifically binds TYRP1.
[0007] The present invention further provides the use of an anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1-specific antibody in the manufacture of a medicament for treating cancer, wherein the anti-TYRP1 / anti-CD3 bispecific antibody comprises a first antigen-binding portion that specifically binds TYRP1 comprising a heavy chain variable domain VH of SEQ ID NO: 1 and a light chain variable domain VL of SEQ ID NO: 2, and a second antigen-binding portion that specifically binds CD3 comprising a heavy chain variable domain VH of SEQ ID NO: 3 and a light chain variable domain VL of SEQ ID NO: 4, and the second TYRP1-specific antibody comprises an antigen-binding portion that specifically binds TYRP1.
[0008] The present invention further provides a method of treating cancer in an individual comprising administering to the individual a therapeutically effective amount of an anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1-specific antibody, wherein the anti-TYRP1 / anti-CD3 bispecific antibody comprises a first antigen-binding portion that specifically binds TYRP1 comprising a heavy chain variable domain VH of SEQ ID NO: 1 and a light chain variable domain VL of SEQ ID NO: 2, and a second antigen-binding portion that specifically binds CD3 comprising a heavy chain variable domain VH of SEQ ID NO: 3 and a light chain variable domain VL of SEQ ID NO: 4, and wherein the second TYRP1-specific antibody comprises an antigen-binding portion that specifically binds TYRP1.
[0009] In one embodiment the second TYRP1 specific antibody comprises a heavy chain variable domain VH of SEQ ID NO:1 and a light chain variable domain VL of SEQ ID NO:2.
[0010] In a further aspect, the anti-TYRP1 / anti-CD3 bispecific antibody is of the human IgG1 or human IgG4 subclass. In one aspect, the second TYRP1 specific antibody is of the human IgG1 subclass.
[0011] In one aspect, the anti-TYRP1 / anti-CD3 bispecific antibody has reduced or minimal effector function. In yet a further aspect, the minimal effector function is due to an effector-less Fc mutation. In one aspect, the effector-less Fc mutation is L234A / L235A or L234A / L235A / P329G or N297A or D265A / N297A.
[0012] The second TYRP1-specific antibody comprises an Fc domain with improved effector function, in particular improved ADCC function. In one embodiment, the second TYRP1-specific antibody is afucosylated.
[0013] In one aspect the invention provides an anti-TYRP1 / anti-CD3 bispecific antibody, use or method in combination with a second TYRP1 specific antibody for use according to any of the preceding aspects, wherein the anti-TYRP1 / anti-CD3 bispecific antibody comprises i) the polypeptide sequence of SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8, ii) the polypeptide sequences of SEQ ID NO:5 and SEQ ID NO:6 and SEQ ID NO:7 and SEQ ID NO:8, or iii) the polypeptide sequences of SEQ ID NO:9 and SEQ ID NO:10 and SEQ ID NO:11 and SEQ ID NO:12.
[0014] In another aspect, the invention provides an anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1 specific antibody for use, use or method according to any of the preceding aspects, wherein the anti-TYRP1 / anti-CD3 bispecific antibody comprises i) the polypeptide sequence of SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8, ii) the polypeptide sequences of SEQ ID NO:5 and SEQ ID NO:6 and SEQ ID NO:7 and SEQ ID NO:8, or iii) the polypeptide sequences of SEQ ID NO:9 and SEQ ID NO:10 and SEQ ID NO:11 and SEQ ID NO:12, and the second TYRP1 specific antibody comprises i) the polypeptide sequence of SEQ ID NO:13 or SEQ ID NO:14, or ii) the polypeptide sequences of SEQ ID NO:13 and SEQ ID NO:14, or iii) the polypeptide sequences of SEQ ID NO:15 and SEQ ID NO:16.
[0015] In one aspect the invention provides an anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1 specific antibody for use in i) inhibiting tumour growth in a tumour and / or ii) improving the median and / or overall survival of subjects bearing a tumour, wherein the anti-TYRP1 / anti-CD3 bispecific antibody comprises i) the polypeptide sequence of SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8, ii) the polypeptide sequences of SEQ ID NO:5 and SEQ ID NO:6 and SEQ ID NO:7 and SEQ ID NO:8, or iii) the polypeptide sequences of SEQ ID NO:9 and SEQ ID NO:10 and SEQ ID NO:11 and SEQ ID NO:12, and the second TYRP1 specific antibody comprises i) the polypeptide sequence of SEQ ID NO:13 or SEQ ID NO:14, or ii) the polypeptide sequences of SEQ ID NO:13 and SEQ ID NO:14, or iii) the polypeptide sequences of SEQ ID NO:15 and SEQ ID NO:16.
[0016] In a further aspect, the invention provides an anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1 specific antibody for use, use or method according to any of the preceding aspects, wherein the cancer is selected from the group of breast cancer, lung cancer, colon cancer, ovarian cancer, melanoma cancer, bladder cancer, renal cancer, kidney cancer, liver cancer, head and neck cancer, colorectal cancer, melanoma, pancreatic cancer, gastric cancer, esophageal cancer, mesothelioma, prostate cancer, leukemia, lymphoma, myeloma. In one aspect, the patient has been treated with immunotherapy or has been pre-treated with immunotherapy. In one aspect, the immunotherapy comprises adoptive cell transfer, administration of a monoclonal antibody, administration of a cytokine, administration of a cancer vaccine, T cell induction therapy, or any combination thereof. In one aspect, adoptive cell transfer comprises administering chimeric antigen receptor-expressing T cells (CAR T cells), T cell receptor (TCR)-modified T cells, tumor infiltrating lymphocytes (TILs), chimeric antigen receptor (CAR)-modified natural killer cells, T cell receptor (TCR)-transduced cells, or dendritic cells, or any combination thereof. [Brief description of the drawings]
[0017] [Figure 1] Figure 1 shows the results of efficacy experiments evaluating muTYRP1-IgG and muTYRP1-TCB as single agents and in combination. B16-muFAP-Fluc double transfectant melanoma cell lines were injected intravenously into Black6 albino mice to investigate survival in a lung metastatic syngeneic model. The amount of antibody injected per mouse (mg / kg) was as follows: 20 mg / kg muTYRP1-IgG and 10 mg / kg muTYRP1-TCB. Antibodies were injected intravenously once a week for 4 weeks. Significantly superior median and overall survival was observed in the 10 mg / kg muTYRP1-TCB + 20 mg / kg muTYRP1-IgG combination group compared to the single agent and vehicle groups tested. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0018] An anti-TYRP1 / anti-CD3 bispecific antibody is described in WO 2020 / 127619.
[0019] The anti-TYRP1 / anti-CD3 bispecific antibodies used in the combination therapy described herein comprise a first antigen-binding portion capable of binding to TYRP1 and a second antigen-binding portion capable of binding to CD3. The anti-TYRP1 / anti-CD3 bispecific antibodies used in the combination therapy described herein comprise a heavy chain variable region sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO:1, or a variant thereof that retains functionality, and a light chain variable region sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO:2, or a variant thereof that retains functionality. and a second antigen-binding portion comprising a heavy chain variable region sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO:3, or a variant thereof that retains functionality, and a light chain variable region sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:4, or a variant thereof that retains functionality. The anti-TYRP1 / anti-CD3 bispecific antibodies used in the combination therapy described herein may comprise a first antigen-binding portion comprising a heavy chain variable domain VH of SEQ ID NO:1 and a light chain variable domain VL of SEQ ID NO:2, and a second antigen-binding portion comprising a heavy chain variable domain VH of SEQ ID NO:3 and a light chain variable domain VL of SEQ ID NO:4.
[0020] The anti-TYRP1 / anti-CD3 bispecific antibodies used in the combination therapy described herein may contain a third antigen-binding moiety identical to the first antigen-binding moiety. In one embodiment, the first and third antigen-binding moieties that bind TYRP1 are conventional Fab molecules. In such an embodiment, the second antigen-binding moiety that binds CD3 is a crossover Fab molecule, i.e., a Fab molecule in which the variable domains VH and VL of the Fab heavy and Fab light chains have been swapped / substituted for each other.
[0021] Anti-TYRP1 / anti-CD3 bispecific antibodies used in combination therapy may contain amino acid substitutions in the Fab molecules contained therein, which are particularly effective in reducing mispairing of light chains with mismatched heavy chains (Bence Jones type by-products) that may occur in the production of Fab-based multispecific antibodies with VH / VL exchanges in one (or more in the case of molecules containing two or more antigen-binding Fab molecules) of the binding arms (see also PCT Publication No. WO 2015 / 150447, particularly the examples therein which are incorporated herein by reference in their entirety). The ratio of desirable (multispecific) antibodies to undesirable by-products, particularly the Bence Jones type by-products that arise in multispecific antibodies with VH / VL domain exchanges in one binding arm, may be improved by introducing charged amino acids with opposite charges at specific amino acid positions in the CH1 and CL domains (sometimes referred to herein as "charge modifications").
[0022] Thus, an anti-TYRP1 / anti-CD3 bispecific antibody for use in combination therapy, in which the first and the second (and, if present, the third) antigen-binding portion of the (multispecific) antibody are Fab molecules, in which in one antigen-binding portion (particularly the second antigen-binding portion) the variable domains VL and VH of the Fab light and heavy chains are replaced by each other, in which in the constant domain CL of the first (and, if present, the third) antigen-binding portion the amino acids at positions 124 and 213 may be replaced by positively charged amino acids (numbering according to Kabat) and in which in the constant domain CH1 of the first (and, if present, the third) antigen-binding portion the amino acids at positions 147 and 213 may be replaced by negatively charged amino acids (numbering according to Kabat EU index). The constant domains CL and CH1 of the antigen-binding portion with VH / VL exchange are not replaced by each other (i.e. remain unexchanged). The amino acids at positions 124 and 213 of the constant domain CL may be independently substituted by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and the amino acids at positions 147 and 213 of the constant domain CH1 may be independently substituted by glutamic acid (E) or aspartic acid (D) (numbering according to Kabat EU index). The anti-TYRP1 / anti-CD3 bispecific antibody used in the combination therapy may have in the constant domain CL of the first (and, if present, the third) antigen binding part an amino acid substitution at position 124 to lysine (K) (numbering according to Kabat), an amino acid substitution at position 123 to arginine (R) (numbering according to Kabat), and in the constant domain CH1 of the first (and, if present, the third) antigen binding domain an amino acid substitution at position 147 to glutamic acid (E) (numbering according to Kabat EU index) and an amino acid substitution at position 213 to glutamic acid (E) (numbering according to Kabat EU index).
[0023] The anti-TYRP1 / anti-CD3 bispecific antibodies used in the combination therapy described herein may have the sequences shown as SEQ ID NOs: 5, 6, 7 and 8, or variants thereof that retain functionality.
[0024] The anti-TYRP1 / anti-CD3 bispecific antibody having the sequences set forth as SEQ ID NOs:5, 6, 7 and 8 is referred to herein as "TYRP1 TCB" or "TYRP1-TCB." The anti-TYRP1 / anti-CD3 bispecific antibody having the sequences set forth as SEQ ID NOs:9, 10, 11 and 12 is referred to herein as "muTYRP1 TCB," which is a murine surrogate antibody.
[0025] Anti-TYRP1 / anti-CD3 bispecific antibodies may comprise an Fc domain that comprises a modification that promotes heterodimerization of two non-identical polypeptide chains. A "heterodimerization-promoting modification" is an engineering of the peptide backbone or a post-translational modification of a polypeptide that reduces or prevents the association of the polypeptide with an identical polypeptide to form a homodimer. A heterodimerization-promoting modification as used herein includes, in particular, separate modifications made to each of the two polypeptides that are desired to form a dimer, which modifications are complementary to each other to promote the association of the two polypeptides. For example, a heterodimerization-promoting modification may alter the structure or charge of one or both of the polypeptides that are desired to form a dimer, so as to make their association sterically or electrostatically favorable, respectively. Heterodimerization occurs between two non-identical polypeptides, for example between two non-identical subunits of an Fc domain. In the bispecific antibodies of the present invention, the heterodimerization-promoting modification is present in the Fc domain. In some embodiments, the heterodimerization-promoting modification comprises an amino acid mutation, specifically an amino acid substitution. In a specific embodiment, the heterodimerization-promoting modification comprises a distinct amino acid mutation, specifically an amino acid substitution, in each of the two subunits of the Fc domain. The most extensive protein-protein interaction site between the two polypeptide chains of the human IgG Fc domain is in the CH3 domain of the Fc domain. Thus, in one embodiment, the modification is in the CH3 domain of the Fc domain. In a specific embodiment, the modification is a knob-into-hole modification, comprising a knob modification in one of the two subunits of the Fc domain and a hole modification in the other of the two subunits of the Fc domain.
[0026] Knob-into-hole technology is described, for example, in U.S. Patent No. 5,731,168, U.S. Patent No. 7,695,936, Ridgway et al., Prot Eng 9, 617-621 (1996), and Carter, J Immunol Meth 248, 7-15 (2001). Typically, the method involves promoting heterodimer formation and hindering homodimer formation by introducing a protuberance ("knob") at the interface of a first polypeptide and a corresponding cavity at the interface of a second polypeptide, respectively, such that the protuberance can be positioned within the corresponding cavity. The protuberance is constructed by replacing a small amino acid side chain from the interface of the first polypeptide with a larger side chain (e.g., tyrosine or tryptophan). A complementary cavity of the same or similar size as the protrusion is created in the interface of the second polypeptide by replacing the large amino acid side chain with a smaller amino acid side chain (e.g., alanine or threonine). The protrusion and cavity can be created by altering the nucleic acid encoding the polypeptide, for example, by site-directed mutagenesis or by peptide synthesis. In a specific embodiment, the knob modification comprises the amino acid substitution T366W in one of the two subunits of the Fc domain, and the hole modification comprises the amino acid substitutions T366S, L368A, and Y407V in the other of the two subunits of the Fc domain. In a more specific embodiment, the subunit of the Fc domain that comprises the knob modification further comprises the amino acid substitution S354C, and the subunit of the Fc domain that comprises the hole modification further comprises the amino acid substitution Y349C. Introduction of these two cysteine residues results in the formation of disulfide bridges between the two subunits of the Fc region, further stabilizing the dimer (Carter, J Immunol Methods 248, 7-15 (2001)).The numbering of amino acid residues in the Fc region is according to the EU numbering system (also called the EU index) as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991. As used herein, a "subunit" of an Fc domain refers to one of the two polypeptides that form a dimeric Fc domain, i.e., a polypeptide that contains the C-terminal constant region of an immunoglobulin heavy chain capable of stable self-association. For example, a subunit of an IgG Fc domain contains the IgG CH2 and IgG CH3 constant domains.
[0027] In another embodiment, modifications that promote heterodimerization of two non-identical polypeptide chains include modifications that mediate electrostatic steering effects, for example as described in WO 2009 / 089004. In general, this method involves the replacement of one or more amino acid residues at the interface of the two polypeptide chains with a charged amino acid residue, such that the formation of homodimers is electrostatically disfavored, while the formation of heterodimers is electrostatically favored.
[0028] The Fc domain of the anti-TYRP1 / anti-CD3 bispecific antibody can be engineered to have altered binding affinity to Fc receptors, specifically to Fcγ receptors, compared to non-engineered Fc domains, as described in WO 2012 / 146628. The binding of the Fc domain to complement components, specifically to C1q, can be altered as described in WO 2012 / 146628. The Fc domain confers favorable pharmacokinetic properties to the antibody, including a long serum half-life that contributes to good accumulation in target tissues and a good tissue-blood distribution ratio. However, it may at the same time lead to undesired targeting of cells expressing Fc receptors rather than the preferred antigen-bearing cells.
[0029] Thus, the Fc domain of an anti-TYRP1 / anti-CD3 bispecific antibody may be engineered to reduce its binding affinity to an Fc receptor. In one such embodiment, the Fc domain comprises one or more amino acid mutations that reduce the binding affinity of the Fc domain to an Fc receptor. Typically, the same one or more amino acid mutations are present in each of the two subunits of the Fc domain. In one embodiment, the amino acid mutations reduce the binding affinity of the Fc domain to an Fc receptor by at least 2-fold, at least 5-fold, or at least 10-fold. In an embodiment where there are two or more amino acid mutations that reduce the binding affinity of the Fc domain to an Fc receptor, the combination of these amino acid mutations reduces the binding affinity of the Fc domain to an Fc receptor by at least 10-fold, at least 20-fold, or even at least 50-fold. In one embodiment, an antibody comprising an engineered Fc domain exhibits less than 20%, particularly less than 10%, more particularly less than 5% of the binding affinity to an Fc receptor compared to an antibody comprising a non-engineered Fc domain. In one embodiment, the Fc receptor is an activating Fc receptor. In a specific embodiment, the Fc receptor is an Fcγ receptor, more specifically an FcγRIIIa, FcγRI or FcγRIIa receptor. Preferably, the binding of each of these receptors is reduced. In some embodiments, the binding affinity to complement components, specifically C1q, is also reduced. In one embodiment, the binding affinity to neonatal Fc receptor (FcRn) is not reduced. Substantially similar binding to FcRn, i.e., preservation of the binding affinity of the Fc domain to the receptor, is achieved when the Fc domain (or an antibody comprising the Fc domain) exhibits more than about 70% of the binding affinity of the unengineered form of the Fc domain (or an antibody comprising the unengineered form of the Fc domain) to FcRn. The Fc domain, or an antibody of the invention comprising the Fc domain, may exhibit more than about 80% or even more than about 90% of such affinity. In one embodiment, the amino acid mutation is an amino acid substitution. In one embodiment, the Fc domain comprises an amino acid substitution at position P329.In a more specific embodiment, the amino acid substitution is P329A or P329G, particularly P329G. In one embodiment, the Fc domain comprises an additional amino acid substitution at a position selected from S228, E233, L234, L235, N297 and P331. In a more specific embodiment, the additional amino acid substitution is S228P, E233P, L234A, L235A, L235E, N297A, N297D or P331S. In a specific embodiment, the Fc domain comprises an amino acid substitution at a position P329, L234 and L235. In a more specific embodiment, the Fc domain comprises amino acid mutations L234A, L235A and P329G (LALA P329G). This combination of amino acid substitutions almost completely eliminates the binding of Fcγ receptors to human IgG Fc domains, as described in WO 2012 / 130831, the entirety of which is incorporated herein by reference. WO 2012 / 130831 also describes methods for preparing such mutant Fc domains and determining their properties, such as Fc receptor binding or effector function. The numbering of amino acid residues in the Fc region follows the EU numbering system (also called the EU index), as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.
[0030] Mutant Fc domains can be prepared by amino acid deletion, substitution, insertion or modification using genetic or chemical methods known in the art and described in WO 2012 / 146628. Genetic methods can include site-directed mutagenesis of the encoding DNA sequence, PCR, gene synthesis, etc. Correct nucleotide changes can be confirmed, for example, by screening.
[0031] In one embodiment, the Fc domain is engineered to have reduced effector function compared to a non-engineered Fc domain, as described in WO 2012 / 146628, including, but not limited to, one or more of the following: reduced complement-dependent cytotoxicity (CDC), reduced antibody-dependent cell-mediated cytotoxicity (ADCC), reduced antibody-dependent cellular phagocytosis (ADCP), reduced cytokine secretion, reduced immune complex-mediated antigen uptake by antigen-presenting cells, reduced binding to NK cells, reduced binding to macrophages, reduced binding to monocytes, reduced binding to polymorphonuclear cells, reduced direct signaling to induce apoptosis, reduced cross-linking of target-bound antibodies, reduced dendritic cell maturation, or reduced T cell priming.
[0032] IgG4 antibodies exhibit reduced binding affinity to Fc receptors and reduced effector functions compared to IgG1 antibodies. Thus, in some embodiments, the Fc domain of the antibody of the invention is an IgG4 Fc domain, in particular a human IgG4 Fc domain. In one embodiment, the IgG4 Fc domain comprises an amino acid substitution at position S228, specifically the amino acid substitution S228P. To further reduce its binding affinity to Fc receptors and / or effector functions, in one embodiment, the IgG4 Fc domain comprises an amino acid substitution at position L235, specifically the amino acid substitution L235E. In another embodiment, the IgG4 Fc domain comprises an amino acid substitution at position P329, specifically the amino acid substitution P329G. In a particular embodiment, the IgG4 Fc domain comprises amino acid substitutions at positions S228, L235, and P329, specifically the amino acid substitutions S228P, L235E, and P329G. Such IgG4 Fc domain mutants and their Fcγ receptor binding properties are described in European Patent Application WO 2012 / 130831, which is incorporated herein by reference in its entirety.
[0033] The TYRP1-specific antibodies used in the combination therapies described herein comprise an antigen-binding portion capable of binding to TYRP1. The TYRP1-specific antibodies used in the combination therapies described herein may comprise an antigen-binding portion comprising a heavy chain variable region sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 1, or a variant thereof that retains function, and a light chain variable region sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 2, or a variant thereof that retains function. The TYRP1-specific antibodies used in the combination therapies described herein may comprise an antigen-binding portion comprising a heavy chain variable domain VH of SEQ ID NO: 1 and a light chain variable domain VL of SEQ ID NO: 2.
[0034] The TYRP1-specific antibody having the sequences set forth in SEQ ID NO:13 and SEQ ID NO:14 is referred to herein as "TYRP1 IgG" or "TYRP1-IgG." The TYRP1-specific antibody having the sequences set forth as SEQ ID NO:15 and SEQ ID NO:16 is referred to herein as "muTYRP1 IgG" or "muTYRP1-IgG," which is the murine surrogate.
[0035] The TYRP1-specific antibodies used in the combination therapies described herein may be antibodies of subclass IgG1. The Fc domain of the TYRP1-specific antibodies may have ADCC activity in the presence of human effector cells, or may have increased ADCC activity compared to an otherwise identical antibody containing a human wild-type IgG1 Fc region.
[0036] In certain embodiments, the antibodies provided herein are modified to increase or decrease the extent to which the antibody is glycosylated. Addition or deletion of glycosylation sites to an antibody can be conveniently accomplished by altering the amino acid sequence such that one or more glycosylation sites are created or removed.
[0037] If the antibody comprises an Fc region, the oligosaccharides attached to the antibody may be altered. Natural antibodies produced by mammalian cells typically contain branched, biantennary oligosaccharides attached by N-linkage to Asn297 in the CH2 domain of the Fc region. See, e.g., Wright et al. TIBTECH 15:26-32 (1997). The oligosaccharides may include various carbohydrates such as mannose, N-acetylglucosamine (GlcNAc), galactose, and sialic acid, as well as fucose attached to GlcNAc at the "stem" of the biantennary oligosaccharide structure. In some embodiments, modifications of the oligosaccharides in the antibodies of the invention may be made to generate antibody variants with specific improved properties.
[0038] In one embodiment, antibody variants are provided that have nonfucosylated oligosaccharides, i.e. oligosaccharide structures that lack fucose linkages (direct or indirect) to the Fc region. Such nonfucosylated oligosaccharides (also called "afucosylated" oligosaccharides) are in particular N-linked oligosaccharides that lack a fucose residue with a first GlcNAc attached to the stem of the biantennary oligosaccharide structure. In one embodiment, antibody variants are provided that have an increased proportion of nonfucosylated oligosaccharides in the Fc region compared to the endogenous or parent antibody. For example, the proportion of nonfucosylated oligosaccharides may be at least about 20%, at least about 40%, at least about 60%, at least about 80% or even about 100% (i.e., no fucosylated oligosaccharides are present). The percentage of nonfucosylated oligosaccharides is the (average) amount of oligosaccharides lacking a fucose residue relative to the sum of all oligosaccharides (e.g., complex, hybrid, and high mannose structures) attached to Asn297, as measured, for example, by MALDI-TOF mass spectrometry as described in WO 2006 / 082515. Asn297 refers to an asparagine residue located at approximately position 297 of the Fc region (EU numbering of Fc region residues). However, due to slight sequence variations in antibodies, Asn297 may also be located approximately ±3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300. Such antibodies with an increased percentage of nonfucosylated oligosaccharides in the Fc region may have improved FcγRIIIa receptor binding and / or improved effector function, in particular improved ADCC function. See, e.g., U.S. Patent Application Publication No. 2003 / 0157108; U.S. Patent Application Publication No. 2004 / 0093621.
[0039] Examples of cell lines capable of producing antibodies with reduced fucosylation include Lec13 CHO cells, which are deficient in protein fucosylation (Ripka et al. Arch. Biochem. Biophys. 249:533-545 (1986); U.S. Patent Application Publication No. 2003 / 0157108; and WO 2004 / 056312, especially Example 11), and knockout cell lines, such as FUT8 knockout CHO cells of the alpha-1,6-fucosyltransferase gene (see, e.g., Yamane-Ohnuki et al. .Biotech.Bioeng.87:614-622 (2004); Kanda, Y. et al., Biotechnol.Bioeng.,94(4):680-688 (2006); and WO 2003 / 085107), or cells with reduced or abolished activity of GDP-fucose synthesis or transporter proteins (see, e.g., U.S. Patent Application Publication Nos. 2004259150, 2005031613, 2004132140, and 2004110282).
[0040] In further embodiments, antibody variants are provided with bisected oligosaccharides, e.g., biantennary oligosaccharides attached to the Fc region of the antibody are bisected by GlcNAc. Such antibody variants may have reduced fucosylation and / or improved ADCC function, as described above. Examples of such antibody variants are described, for example, in Umana et al., Nat Biotechnol 17, 176-180 (1999); Ferrara et al., Biotechn Bioeng 93, 851-861 (2006); WO 99 / 54342, WO 2004 / 065540, WO 2003 / 011878.
[0041] Also provided is an antibody variant that has at least one galactose residue in the oligosaccharide attached to Fc region.Such an antibody variant can have improved CDC function.Examples of such antibody variants are described in, for example, WO 1997 / 30087; WO 1998 / 58964; and WO 1999 / 22764.
[0042] The Fc domain of the TYRP1-specific antibody may contain one or more amino acid substitutions that improve ADCC by increasing binding to the Fc receptor, preferentially FcγRIII. The Fc domain may contain amino acid substitutions at positions 298, 333 and / or 334 of the Fc region (EU numbering of residues) (Shields et al., J Biol Chem. 276(9):6591-604(2001)). Further examples of such Fc variants are described in Wang et al., Protein Cell. 9(1):63-73(2018); and Nordstrom et al., Breast Cancer Res. 13(6):R123(2011).
[0043] In certain embodiments, TYRP1 specific antibody variants comprising an Fc region described herein are capable of binding to FcγRIII. In certain embodiments, antibody variants comprising an Fc region described herein have ADCC activity in the presence of human effector cells or have increased ADCC activity in the presence of human effector cells compared to an otherwise identical antibody comprising a human wild-type IgG1 Fc region.
[0044] definition The term "antibody" is used in the broadest sense herein and encompasses various antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, and antibody fragments, so long as they exhibit the desired antigen-binding activity. An "antibody fragment" refers to a molecule other than an intact antibody that contains a portion of an intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2, diabodies, linear antibodies, single-chain antibody molecules (e.g., scFv), and single-domain antibodies. For a review of specific antibody fragments, see Hudson et al., Nat Med. 9, 129-134 (2003).
[0045] The term "antigen-binding portion", "antigen-binding domain" or "antigen-binding portion of an antibody" as used herein refers to a portion of an antibody that comprises the region that specifically binds and is complementary to a part or all of an antigen. Thus, the term refers to the amino acid residues of an antibody that are responsible for antigen binding. An antigen-binding domain may be provided, for example, by one or more antibody variable domains (also called antibody variable regions). In particular, an antigen-binding domain comprises an antibody light chain variable domain (VL) and an antibody heavy chain variable domain (VH). The antigen-binding portion of an antibody comprises amino acid residues from the "complementarity determining regions" or "CDRs". "Framework" or "FR" regions are the variable domain regions other than the hypervariable region residues as defined herein. Thus, the variable domains of the light and heavy chains of an antibody comprise, from the N-terminus to the C-terminus, the domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. In particular, the CDR3 of the heavy chain is the region that contributes most to antigen binding and defines the properties of the antibody. The CDR and FR regions are determined according to the standard definition of Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991) and / or residues from "hypervariable loops". The term "variable region" or "variable domain" refers to the domain of the heavy or light chain of an antibody that is involved in binding the antibody to an antigen. The variable domains of the heavy and light chains of natural antibodies (VH and VL, respectively) generally have a similar structure, and each domain contains four conserved framework regions (FR) and three hypervariable regions (HVR). See, for example, Kindt et al., Kuby Immunology, 6th, WH Freeman and Co., page 91 (2007). A single VH or VL domain may be sufficient to confer antigen-binding specificity.
[0046] The term "epitope" refers to a protein determinant of an antigen, such as TYRP1 or human CD3, that can specifically bind to an antibody. Epitopes usually consist of chemically active surface groupings of molecules, such as amino acids or sugar side chains, and usually have specific three-dimensional structural properties, as well as specific charge characteristics. Conformational and nonconformational epitopes are distinguished in that the binding to the former, but not the latter, is lost in the presence of denaturing solvents.
[0047] The term "Fc domain" or "Fc region" herein is used to define the C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. This term includes native sequence Fc regions and variant Fc regions. Although the boundaries of the Fc region of an IgG heavy chain may vary slightly, the human IgG heavy chain Fc region is usually defined to extend from Cys226 or from Pro230 to the carboxy terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may be present or absent. Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991. The Fc domain of an antibody is not directly involved in binding the antibody to an antigen, but exhibits various effector functions. "Antibody Fc domain A" is a term well known to those skilled in the art and is defined based on papain cleavage of antibodies. Depending on the amino acid sequence of the constant region of the heavy chain, antibodies or immunoglobulins are classified into classes: IgA, IgD, IgE, IgG, and IgM, some of which can be further classified into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, and IgG4, IgA1, and IgA2. According to the heavy chain constant region, the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively. The Fc domain of an antibody is directly involved in complement activation, ADCC (antibody-dependent cell-mediated cytotoxicity) and CDC (complement-dependent cytotoxicity) based on C1q binding and Fc receptor binding. Complement activation (CDC) is initiated by the binding of the complement factor C1q to the Fc domain of most IgG antibody subclasses. Although the effect of antibodies on the complement system depends on certain conditions, the binding to C1q is triggered by a defined binding site in the Fc domain.Such binding sites are known in the state of the art and are described, for example, in Boackle, RJ et al., Nature 282 (1979) 742-743; Lukas, TJ et al., J. Immunol. 127 (1981) 2555-2560; Brunhouse, R. and Cebra, JJ, Mol. Immunol. 16 (1979) 907-917; Burton, DR et al., Nature 288 (1980) 338-344; Thommesen, JE et al., Mol. Immunol. 37 (2000) 995-1004; Idusogie, EE et al., J. Immunol. 164 (2000) 4178-4184; Hezareh, M. et al., J. Virology 75 (2001) 12161-12168; Morgan, A. et al., Immunology 86 (1995) 319-324, and in European Patent No. 0307434. Such binding sites are, for example, L234, L235, D270, N297, E318, K320, K322, P331 and P329 (see EU index of Kabat, supra, EA). Antibodies of the subclasses IgG1, IgG2 and IgG3 usually exhibit complement activation and binding to C1q and C3, whereas IgG4 does not activate the complement system and does not bind C1q and C3.
[0048] In one embodiment, the antibody described herein comprises an Fc domain derived from human origin, preferably all other parts of the human constant region. As used herein, the term "Fc domain derived from human origin" refers to an Fc domain of a human antibody of IgG1, IgG2, IgG3 or IgG4 subclass, preferably an Fc domain derived from human IgG1 subclass, a mutated Fc domain derived from human IgG1 subclass, an Fc domain derived from human IgG4 subclass or a mutated Fc domain derived from human IgG4 subclass. In one embodiment, the anti-TRYP1 / anti-CD3 bispecific antibody has reduced or minimal effector function. In one embodiment, the minimal effector function is due to an effectorless Fc mutation. In one embodiment, the effectorless Fc mutation is L234A / L235A or L234A / L235A / P329G or N297A or D265A / N297A. In one embodiment, the effectorless Fc mutations are selected for each of the antibodies independent of each other from the group comprising (consisting of): L234A / L235A, L234A / L235A / P329G, N297A and D265A / N297A (EU numbering). In one embodiment, the TYRP1 specific antibody has ADCC activity in the presence of human effector cells or has increased ADCC activity in the presence of human effector cells compared to an otherwise identical antibody comprising a human wild type IgG1 Fc region. In one embodiment, an antibody variant is provided comprising an Fc region, wherein the carbohydrate structure attached to the Fc region has reduced fucose or lacks fucose.
[0049] An "activating Fc receptor" is an Fc receptor that, following engagement by the Fc region of an antibody, triggers signaling events that stimulate a receptor-bearing cell to execute an effector function. Activating Fc receptors include FcγRIIIa (CD16a), FcγRI (CD64), FcγRIIa (CD32) and FcαRI (CD89). The term "effector function", when used in reference to an antibody, refers to the biological activity attributable to the Fc region of the antibody, which varies with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement-dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); antibody-dependent cellular phagocytosis (ADCP); cytokine secretion; immune complex-mediated antigen uptake by antigen-presenting cells; downregulation of cell surface receptors (e.g., B cell receptor); and activation of B cells.
[0050] In one embodiment, the antibodies described herein are of the human IgG class (i.e., IgG1, IgG2, IgG3 or IgG4 subclass).
[0051] In a preferred embodiment, the antibodies described herein are of the IgG1 or human IgG4 subclass. In one embodiment, the antibodies described herein are of the human IgG1 subclass. In one embodiment, the antibodies described herein are of the human IgG4 subclass.
[0052] In one embodiment, the antibodies described herein are characterized in that the constant chains are of human origin. Such constant chains are well known in the state of the art and are described, for example, in Kabat, EA, (see, for example, Johnson, G. and Wu, TT, Nucleic Acids Res. 28 (2000) 214-218).
[0053] As used herein, the terms "first," "second," or "third" with respect to an antibody, Fc domain subunit, antigen-binding portion, etc., are used for convenience to distinguish when there are two or more different forms of each type, i.e., various antibodies, Fc domain subunits, antigen-binding portions. The use of these terms is not intended to confer a particular order or orientation unless expressly indicated as such.
[0054] The term "nucleic acid" or "nucleic acid molecule" as used herein is intended to include DNA molecules and RNA molecules. A nucleic acid molecule may be single-stranded or double-stranded, but is preferably double-stranded DNA.
[0055] As used in this application, the term "amino acid" refers to the group of naturally occurring carboxy α-amino acids including alanine (three letter code: ala, one letter code: A), arginine (arg, R), asparagine (asn, N), aspartic acid (asp, D), cysteine (cyan, C), glutamine (gln, Q), glutamic acid (glu, E), glycine (gly, G), histidine (his, H), isoleucine (ile, I), leucine (leu, L), lysine (lys, K), methionine (met, M), phenylalanine (phe, F), proline (pro, P), serine (ser, S), threonine (thr, T), tryptophan (trp, W), tyrosine (tyr, Y) and valine (val, V).
[0056] "Percentage (%) amino acid sequence identity" with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in the reference polypeptide sequence after performing sequence alignment and introducing gaps, if necessary, to achieve the maximum percent sequence identity, without considering any conservative substitutions as part of the sequence identity. Alignment for the purpose of determining percent amino acid sequence identity can be achieved in a variety of ways that are within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine the appropriate parameters for sequence alignment, including any algorithms required to achieve maximum alignment over the entire length of the sequences being compared. However, for the purposes herein, percent amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was written by Genentech, Inc., and the source code, together with user documentation, has been filed with the U.S. Copyright Office, Washington DC, 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or may be compiled from its source code. The ALIGN-2 program should be compiled for use on UNIX operating systems, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.In situations where ALIGN-2 is used for amino acid sequence comparison, the % amino acid sequence identity for a given amino acid sequence A to a given amino acid sequence B, or of a given amino acid sequence A with a given amino acid sequence B, or of a given amino acid sequence A to a given amino acid sequence B (or alternatively, a given amino acid sequence A having or containing a certain % amino acid sequence identity to a given amino acid sequence B, with a given amino acid sequence B, or to a given amino acid sequence B) is calculated as follows: 100 x fraction X / Y where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in the alignment of A and B in the program, and Y is the total number of amino acid residues in B. It will be understood that if the length of amino acid sequence A is not equal to the length of amino acid sequence B, the amino acid sequence identity % of A to B is not equal to the amino acid sequence identity % of B to A. Unless otherwise stated, all amino acid sequence identity % values used herein are obtained using the ALIGN-2 computer program as described in the immediately preceding paragraph. A nucleic acid or polynucleotide having a nucleotide sequence that is, for example, at least 95% "identical" to a reference nucleotide sequence of the present invention means that the nucleotide sequence of the polynucleotide is identical to the reference sequence, except that it may contain up to 5 point mutations per each 100 nucleotides of the reference nucleotide sequence. In other words, to obtain a polynucleotide having a nucleotide sequence that is at least 95% identical to the reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or replaced with another nucleotide, or up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur either individually among the residues in the reference sequence or interspersed in one or more contiguous groups within the reference sequence, at the 5' or 3' terminal positions of the reference nucleotide sequence, or anywhere between the residues in the reference sequence at those terminal positions. As a practical matter, whether any particular polynucleotide sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the invention can be conventionally determined using known computer programs, such as those described above for polypeptides (e.g., ALIGN-2).
[0057] Provided is a method of producing an antibody described herein, comprising culturing a host cell containing a polynucleotide encoding an antibody as provided herein under conditions suitable for expression of the antibody, and recovering the antibody from the host cell (or host cell culture medium).
[0058] An antibody comprises at least an antibody variable region capable of binding to an antigenic determinant. The variable region may form part of and be derived from naturally occurring or non-naturally occurring antibodies and fragments thereof. Methods for generating polyclonal and monoclonal antibodies are well known in the art (see, e.g., Harlow and Lane, "Antibodies, a laboratory manual", Cold Spring Harbor Laboratory, 1988). Non-naturally occurring antibodies may be constructed using solid-phase peptide synthesis, may be recombinantly produced (e.g., as described in U.S. Pat. No. 4,186,567), or may be obtained, for example, by screening a combinatorial library containing variable heavy and variable light chains (see, e.g., U.S. Pat. No. 5,969,108 to McCafferty). Antigen-binding moieties and methods for producing them are also described in detail in PCT Publication No. WO2011 / 020783, the entire contents of which are incorporated herein by reference.
[0059] Any animal species of antibody, antibody fragment, antigen-binding domain or variable region can be used in the antibody described herein.Non-limiting antibodies, antibody fragments, antigen-binding domains or variable regions useful in the present invention can be of mouse, primate or human origin.When the antibody is intended for human use, the chimeric form of the antibody can be used, in which the constant region of the antibody is of human origin.Humanized or fully human forms of antibodies can also be prepared according to methods well known in the art (see, for example, U.S. Patent No. 5,565,332). Humanization may be achieved by a variety of methods, including, but not limited to, (a) grafting the CDRs of a non-human (e.g., a donor antibody) onto human (e.g., a recipient antibody) framework and constant regions, with or without retaining key framework residues (e.g., those important for maintaining good antigen binding affinity or antibody function); (b) grafting only non-human specificity determining regions (SDRs or a-CDRs; residues important for antibody-antigen interaction) onto human framework and constant regions; or (c) grafting entire non-human variable domains but "cloaking" them with human-like segments by replacement of surface residues.Humanized antibodies and methods for their production are reviewed, e.g., in Almagro and Fransson, Front Biosci 13, 1619-1633 (2008), and are described, e.g., in Riechmann et al., Nature 332, 323-329 (1988); Queen et al., Proc Natl Acad Sci USA 86, 10029-10033 (1989); U.S. Patent Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Jones et al., Nature 321, 522-525 (1986); Morrison et al., Proc Natl Acad Sci 81, 6851-6855 (1984); Morrison and Oi, Adv Immunol 44, 65-92 (1988); Verhoeyen et al., Science 239, 1534-1536 (1988); Padlan, Molec Immun 31(3), 169-217 (1994); Kashmiri et al., Methods 36, 25-34 (2005) (describing SDR(a-CDR) grafting); Padlan, Mol Immunol 28, 489-498 (1991) (describing "resurfacing"); Dall'Acqua et al., Methods 36, 43-60 (2005) (describing "FR shuffling"); and Osbourn et al., Methods 36, 61-68 (2005) and Klimka et al., Br J Cancer 83, 252-260 (2000) (describing a "guided selection" approach to FR shuffling). Human antibodies and human variable regions can be generated using a variety of techniques known in the art. Human antibodies are generally described in van Dijk and van de Winkel, Curr Opin Pharmacol. 5, 368-74 (2001) and Lonberg, Curr Opin Immunol 20, 450-459 (2008).Human variable regions may form part of, and be obtained from, human monoclonal antibodies produced by hybridoma technology (see, e.g., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)). Human antibodies and human variable regions may also be prepared by administering an immunogen to transgenic animals that have been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigen challenge (see, e.g., Lonberg, Nat Biotech 23, 1117-1125 (2005)). Human antibodies and human variable regions can also be generated by isolating Fv clone variable region sequences selected from a human-derived phage display library (see, e.g., Hoogenboom et al. in Methods in Molecular Biology 178, 1-37 (O'Brien et al., eds., Human Press, Totowa, NJ, 2001); and McCafferty et al., Nature 348, 552-554; Clackson et al., Nature 352, 624-628 (1991)). Phage typically display antibody fragments, either as single-chain Fv (scFv) fragments or as Fab fragments.
[0060] In certain embodiments, the antibodies are described, for example, in PCT Publication WO 2011 / 020783 (see Examples on Affinity Maturation) or US Patent Publication No. 2004 / 0132066, the entire contents of which are incorporated herein by reference. The ability of an antibody to bind to a specific antigenic determinant can be measured by either enzyme-linked immunosorbent assay (ELISA) or other techniques well known to those skilled in the art, such as surface plasmon resonance techniques (analyzed on a BIACORE T 100 system) (Liljeblad et al., Glyco J 17, 323-329 (2000)) and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)). Competitive assays may be used to identify antibodies, antibody fragments, antigen-binding domains or variable domains that compete with a reference antibody for binding to a particular antigen. In some embodiments, such competing antibodies bind to the same epitope (e.g., linear or conformational epitope) as that bound by the reference antibody. Detailed exemplary methods for mapping epitopes to which antibodies bind are provided in Morris (1996) "Epitope Mapping Protocols" in Methods in Molecular Biology vol. 66 (Humana Press, Totowa, NJ). In an exemplary competitive assay, immobilized antigen is incubated in a solution containing a first labeled antibody that binds to the antigen and a second unlabeled antibody that is being tested for its ability to compete with the first antibody for binding to the antigen. The second antibody may be present in the hybridoma supernatant. As a control, immobilized antigen is incubated in a solution containing the first labeled antibody but not the second unlabeled antibody. After incubation under conditions that allow binding of the first antibody to the antigen, excess unbound antibody is removed and the amount of label associated with the immobilized antigen is measured. If the amount of label associated with the immobilized antigen is substantially reduced in the test sample compared to the control sample, it indicates that the second antibody is competing with the first antibody for binding to the antigen.See Harlow and Lane (1988) Antibodies: A Laboratory Manual ch. 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).
[0061] The anti-TYRP1 / anti-CD3 bispecific antibodies described herein may be prepared as described in the Examples of WO 2020 / 127619.
[0062] The antibodies described herein are preferably produced by recombinant means. Such methods are widely known in the state of the art and include protein expression in prokaryotic and eukaryotic cells followed by isolation of the antibody polypeptide and purification, usually to a pharmaceutically acceptable degree of purity. For protein expression, nucleic acids encoding the light and heavy chains or fragments thereof are inserted into expression vectors by standard methods. Expression is carried out in suitable prokaryotic and eukaryotic host cells such as CHO cells, NS0 cells, SP2 / 0 cells, HEK293 cells, COS cells, yeast or E. coli cells, and the antibody is recovered from the cells (from the supernatant or after cell lysis).
[0063] Recombinant production of antibodies is well known in the state of the art and is described, for example, in the reviews of Makrides, SC, Protein Expr. Purif. 17 (1999) 183-202; Geisse, S. et al., Protein Expr. Purif. 8 (1996) 271-282; Kaufman, RJ, Mol. Biotechnol. 16 (2000) 151-161; Werner, RG, Drug Res. 48 (1998) 870-880.
[0064] The antibody may be present in whole cells, in cell lysates, or in partially purified or substantially pure form. Purification is carried out to eliminate other cellular components or other contaminants, such as other cellular nucleic acids or proteins, by standard techniques including alkaline / SDS treatment, CsCl banding, column chromatography, agarose gel electrophoresis, and others well known in the art. See Ausubel, F. et al., eds. Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York (1987).
[0065] Expression in NS0 cells is described, for example, in Barnes, LM, et al., Cytotechnology 32 (2000) 109-123; Barnes, LM, et al., Biotech. Bioeng. 73 (2001) 261-270. Transient expression is described, for example, in Durocher, Y., et al., Nucl. Acids. Res. 30 (2002) E9. Cloning of variable domains is described, for example, in Orlandi, R., et al., Proc. Natl. Acad. Sci. USA 86 (1989) 3833-3837; Carter, P., et al., Proc. Natl. Acad. Sci. USA 89 (1992) 4285-4289; Norderhaug, L., et al., J. Immunol. Methods 204 (1997) 77-87. A preferred transient expression system (HEK 293) is described by Schlaeger, E.-J., and Christensen, K., Cytotechnology 30 (1999) 71-83, and by Schlaeger, E.-J., J. Immunol. Methods 194 (1996) 191-199.
[0066] The heavy and light chain variable regions according to the invention are combined with promoter, translation initiation, constant region, 3' untranslated region, polyadenylation, and transcription termination sequences to form an expression vector construct. The heavy and light chain constructs are combined in a single vector and either co-transfected, sequentially transfected, or separately transfected into a host cell, which are then fused to form a single host cell expressing both chains.
[0067] For example, control sequences that are suitable for prokaryotes include a promoter, optionally an operator sequence, and a ribosome binding site, while eukaryotic cells are known to utilize promoters, enhancers, and polyadenylation signals.
[0068] A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence, or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading frame. Enhancers, however, need not be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
[0069] Monoclonal antibodies are preferably separated from culture medium by conventional immunoglobulin purification procedures, such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography. The DNA and RNA encoding monoclonal antibodies are easily isolated and sequenced using conventional procedures. Hybridoma cells can serve as the source of such DNA and RNA. Once isolated, DNA can be inserted into an expression vector, and the expression vector is then transfected into host cells, such as HEK293 cells, CHO cells, or myeloma cells, that do not otherwise produce immunoglobulin protein, to obtain the synthesis of recombinant monoclonal antibodies in the host cells.
[0070] As used herein, the terms "cell", "cell line" and "cell culture" are used interchangeably, and all such terms include progeny. Thus, the terms "transformant" and "transformed cell" include the primary subject cell and the cultures derived therefrom, regardless of the number of times the cell has been transferred. It is also understood that all progeny may not be exactly identical in DNA content due to deliberate or unintended mutations. Variant progeny that have the same function or biological activity as screened for in the original transformed cell are included.
[0071] Therapeutic Methods and Compositions The present invention includes a method of treating a patient in need of treatment comprising administering to the patient a therapeutically effective amount of a combination therapy of an anti-TYRP1 / anti-CD3 bispecific antibody and a TYRP1-specific antibody.
[0072] The present invention includes the use of anti-TYRP1 / anti-CD3 bispecific antibodies and TYRP1 specific antibodies according to the invention for the combination therapy described.
[0073] A preferred embodiment of the invention is a combination therapy of an anti-TYRP1 / anti-CD3 bispecific antibody of the invention with a TYRP1-specific antibody for use in the treatment of cancer or tumor. Accordingly, one embodiment of the invention is an anti-TYRP1 / anti-CD3 bispecific antibody as described herein for use in the treatment of cancer or tumor in combination with a TYRP1-specific antibody as described herein. Another embodiment of the invention is a TYRP1-specific antibody as described herein for use in the treatment of cancer or tumor in combination with an anti-TYRP1 / anti-CD3 bispecific antibody as described herein.
[0074] The term "cancer" as used herein includes, for example, lung cancer, non-small cell lung cancer (NSCL), bronchioloalveolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, stomach cancer, gastric cancer, and the like. The cancer may be colon cancer, breast cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, bladder cancer, kidney or ureter cancer, renal cell carcinoma, renal pelvis cancer, mesothelioma, hepatocellular carcinoma, bile duct cancer, central nervous system (CNS) neoplasms, spinal tumors, brain stem glioma, glioblastoma multiforme, astrocytoma, neurinoma, ependymoma, medulloblastoma, meningioma, squamous cell carcinoma, pituitary adenoma, lymphoma, lymphocytic leukemia, including refractory forms of any of the above cancers, or a combination of one or more of the above cancers. In a preferred embodiment, such cancer is breast cancer, colorectal cancer, melanoma, head and neck cancer, lung cancer, or prostate cancer. In a preferred embodiment, such cancer is breast cancer, ovarian cancer, cervical cancer, lung cancer, or prostate cancer. In another preferred embodiment, such cancer is breast cancer, lung cancer, colon cancer, ovarian cancer, melanoma cancer, bladder cancer, renal cancer, kidney cancer, liver cancer, head and neck cancer, colorectal cancer, pancreatic cancer, gastric cancer, esophageal cancer, mesothelioma, prostate cancer, leukemia, lymphoma, myeloma. In a preferred embodiment, such cancer is a TYRP1 expressing cancer.
[0075] One embodiment of the present invention is an anti-TYRP1 / anti-CD3 bispecific antibody as described herein in combination with a TYRP1 specific antibody as described herein for use in the treatment of any of the above mentioned cancers or tumors. Another embodiment of the present invention is an anti-TYRP1 / anti-CD3 bispecific antibody as described herein in combination with a TYRP1 specific antibody as described herein for use in the treatment of any of the above mentioned cancers or tumors. The present invention includes combination therapy of an anti-TYRP1 / anti-CD3 bispecific antibody as described herein and a TYRP1 specific antibody as described herein for the treatment of cancer. The present invention includes combination therapy of an anti-TYRP1 / anti-CD3 bispecific antibody as described herein and a TYRP1 specific antibody as described herein for the prevention or treatment of metastasis.
[0076] The present invention includes methods for treating cancer in a patient in need of such treatment, comprising administering to the patient an anti-TYRP1 / anti-CD3 bispecific antibody as described herein and a TYRP1 specific antibody as described herein.The present invention includes methods for the prevention or treatment of metastasis in a patient in need of such treatment, comprising administering to the patient an anti-TYRP1 / anti-CD3 bispecific antibody as described herein and a TYRP1 specific antibody as described herein.
[0077] The present invention includes anti-TYRP1 / anti-CD3 bispecific antibodies as described herein for use in combination with a TYRP1-specific antibody as described herein for the treatment of cancer, or for the manufacture of a medicament for the treatment of cancer in combination with a TYRP1-specific antibody as described herein.
[0078] The present invention includes the anti-TYRP1 / anti-CD3 bispecific antibodies described herein for use in combination with a TYRP1-specific antibody described herein for the prevention or treatment of metastasis, or for the manufacture of a medicament for the prevention or treatment of metastasis in combination with a TYRP1-specific antibody described herein.
[0079] The present invention includes the TYRP1-specific antibodies described herein for use in combination with the anti-TYRP1 / anti-CD3 bispecific antibodies described herein for the treatment of cancer, or for the manufacture of a medicament for the treatment of cancer in combination with the anti-TYRP1 / anti-CD3 bispecific antibodies described herein.
[0080] The present invention includes the TYRP1-specific antibodies described herein for use in combination with the anti-TYRP1 / anti-CD3 bispecific antibodies described herein for the prevention or treatment of metastasis, or for the manufacture of a medicament for the prevention or treatment of metastasis in combination with the anti-TYRP1 / anti-CD3 bispecific antibodies described herein.
[0081] In a preferred embodiment of the present invention, the anti-TYRP1 / anti-CD3 bispecific antibodies used in the combined treatment and medical uses of the above mentioned different diseases are anti-TYRP1 / anti-CD3 bispecific antibodies characterized in that they comprise the polypeptide sequences of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, and the TYRP1 specific antibodies used in such combined treatment are characterized in that they comprise the polypeptide sequences of SEQ ID NO:13 and SEQ ID NO:14.
[0082] In another aspect, the present invention provides compositions, e.g., pharmaceutical compositions, comprising an anti-TYRP1 / anti-CD3 bispecific antibody as described herein and a TYRP1-specific antibody as described herein, formulated together with a pharma- ceutically acceptable carrier.
[0083] As used herein, "pharmaceutically acceptable carriers" include any and all physiologically compatible antibodies, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption / resorption delaying agents, etc. Preferably, the carrier is suitable for injection or infusion.
[0084] The compositions of the present invention can be administered by a variety of methods known in the art. As will be appreciated by those of skill in the art, the route and mode of administration will vary depending on the desired results.
[0085] Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for preparing sterile injectable solutions or dispersions.The use of such media and agents for pharma-ceutically active substances is known in the art.In addition to water, carriers can be, for example, isotonic buffered saline.
[0086] Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and / or the pharmaceutical compositions of the present invention, are formulated into pharma- ceutically acceptable dosage forms by conventional methods known to those skilled in the art.
[0087] The actual dosage level of the active ingredient in the pharmaceutical composition of the present invention may be varied to obtain an amount of the active ingredient (effective amount) that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration without causing toxicity to the patient. The dosage level selected will depend on various pharmacokinetic factors, including the activity of the particular composition of the present invention, or its ester, salt, or amide, used, the mode of administration, the time of administration, the excretion rate of the particular compound used, other drugs, compounds and / or materials used in combination with the particular composition used, the age, sex, weight, condition, overall health and medical history of the patient being treated, and similar factors well known in the medical arts.
[0088] In one aspect, the invention provides a kit intended for the treatment of a disease, comprising (a) an anti-TYRP1 / anti-CD3 bispecific antibody as described herein, and (b) a TYRP1-specific antibody as described herein, in the same or separate containers, and optionally further comprising (c) a package insert comprising printed instructions directing the use of the combined treatment as a method for treating the disease. Additionally, the kit may comprise (a) a first container housing a composition comprising an anti-TYRP1 / anti-CD3 bispecific antibody as described herein; (b) a second container housing a composition comprising a TYRP1-specific antibody as described herein; and optionally (c) a third container with a composition contained therein, the composition comprising an additional cytotoxic or other therapeutic agent. The kit in this embodiment may further comprise a package insert indicating that the composition may be used to treat a particular condition. Alternatively, or additionally, the kit may further comprise a third (or fourth) container containing a pharma- ceutically acceptable buffer (e.g., bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, or dextrose solution). The article of manufacture may further comprise other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
[0089] In another aspect, the invention provides a kit intended for the treatment of a disease comprising (a) a container containing an anti-TYRP1 / CD3 antibody described herein, and (b) a package insert directing the use of the anti-TYRP1 / anti-CD3 antibody in combination therapy with a TYRP1-specific antibody described herein as a method for treating the disease.
[0090] In another aspect, the invention provides a kit intended for the treatment of a disease comprising (a) a container containing a TYRP1-specific antibody described herein, and (b) a package insert containing instructions directing the use of the TYRP1-specific antibody in combination therapy with an anti-TYRP1 / anti-CD3 antibody described herein as a method of treating the disease.
[0091] In a further aspect, the present invention provides a medicament intended for the treatment of a disease comprising an anti-TYRP1 / anti-CD3 antibody as described herein, which is for use in combination therapy with a TYRP1 specific antibody as described herein, and optionally comprises a package insert comprising printed instructions directing the use of the combination treatment as a method for treating the disease.
[0092] In a still further aspect, the present invention provides a medicament intended for the treatment of a disease comprising a TYRP1-specific antibody as described herein, which is for use in combination treatment with an anti-TYRP1 / anti-CD3 antibody as described herein, optionally comprising a package insert comprising printed instructions directing the use of the combination treatment as a method for treating the disease.
[0093] The term "method of treatment" or its equivalents, for example, when applied to cancer, refers to a treatment or course of action designed to reduce or eliminate the number of cancer cells in a patient, or to alleviate the symptoms of cancer. A "method of treatment" of cancer or another proliferative disease does not necessarily mean that cancer cells or other disorders are actually eliminated, that the number of cells or disorders is actually reduced, or that the symptoms of cancer or other disorders are actually alleviated. In many cases, a method of treating cancer is carried out even when the probability of success is low, but is still considered to induce a course of action that is overall beneficial, given the patient's medical history and estimated survival.
[0094] The terms "administered in combination with" or "co-administration", "concurrent administration", "combination therapy" or "combination treatment" refer to the administration of an anti-TYRP1 / anti-CD3 bispecific antibody and a TYRP1 specific antibody as described herein, for example, as separate formulations / applications (or a single formulation / application). Co-administration may be simultaneous or sequential in either order, and it is desirable that there is a period during which both (or all) active agents exert their biological activity simultaneously. The active agents are co-administered (e.g., intravenously (i,v.)) either simultaneously or sequentially through continuous infusion. When both therapeutic agents are co-administered sequentially, the doses are administered on the same day in two separate administrations, or one of the agents is administered on day 1 and the second agent is co-administered from day 2 to day 7, preferably from day 2 to day 4. Thus, in one embodiment, the term "sequentially" means within 7 days after administration of the first component, preferably within 4 days after administration of the first component, and the term "concurrently" means administration at the same time. The term "co-administration" with respect to maintenance doses of anti-TYRP1 / anti-CD3 antibody and / or TYRP1-specific antibody means that the maintenance doses may be co-administered simultaneously, e.g., weekly, if treatment cycles are appropriate for both drugs, or the maintenance doses are co-administered continuously, e.g., doses of anti-TYRP1 / anti-CD3 antibody and TYRP1-specific antibody are administered on alternating weeks.
[0095] It will be apparent that the antibodies are administered to a patient in a "therapeutically effective amount" (or simply "effective amount"), that is that amount of each compound or combination that elicits the biological or medical response in a tissue, system, animal, or human that is being sought by the researcher, veterinarian, physician, or other clinician.
[0096] The amount of co-administration and the timing of co-administration will depend on the type (species, sex, age, weight, etc.) and condition of the patient being treated and the severity of the disease or condition being treated. The anti-TYRP1 / anti-CD3 antibodies and / or TYRP1-specific antibodies are suitably co-administered to the patient at once or over a series of treatments, for example on the same day or on subsequent days or at weekly intervals.
[0097] In addition to the anti-TYRP1 / anti-CD3 antibody in combination with a TYRP1-specific antibody, a chemotherapeutic agent may also be administered.
[0098] In one embodiment, such additional chemotherapeutic agents that may be administered with the anti-TYRP1 / anti-CD3 antibodies described herein and the TYRP1-specific antibodies described herein include anti-tumor agents, including alkylating agents, including, but not limited to: nitrogen mustards, such as mechlorethamine, cyclophosphamide, ifosfamide, melphalan, and chlorambucil; nitrosoureas, such as carmustine (BCNU), lomustine (CCNU), semustine (methyl-CCNU); Temodal ( Ethyleneimines / methylmelamines such as tetracycline (Temozolamide), triethylenemelamine (TEM), triethylene,thiophosphoramide (thiotepa), and hexamethylmelamine (HMM, altretamine); alkylsulfonates such as busulfan; triazines such as dacarbazine (DTIC); folate analogs such as methotrexate and trimetrexate, 5-fluorouracil (5FU), fluorodeoxyuridine, gemcitabine, cytosine arabinoside (AraC, cytarabine), 5-azabicyclo[4.2.1]phenylmethylsulfonates such as tetracycline (Trimethylolpropane), ... antimetabolites, including pyrimidine analogues such as cytidine, 2,2'-difluorodeoxycytidine, 6-mercaptopurine, 6-thioguanine, azathioprine, T-deoxycoformycin (pentostatin), purine analogues such as erythrohydroxynonyladenine (EHNA), fludarabine phosphate, and 2-chlorodeoxyadenosine (cladribine, 2-CdA); antimitotics, such as paclitaxel, vinca alkaloids, including vinblastine (VLB), vincristine, and vinorelbine, taxa. natural products including teel, estramustine, and estramustine phosphate; hypodophyllotoxins such as etoposide and teniposide; antibiotics such as actinomycin D, daunomycin (rubidomycin), doxorubicin, mitoxantrone, idarubicin, bleomycin, plicamycin (mithramycin), mitomycin C, and actinomycin; enzymes such as L-asparaginase; biological response modifiers such as interferon-alpha, IL-2, G-CSF, and GM-CSF;miscellaneous agents including platinum coordination complexes such as oxaliplatin, cisplatin and carboplatin, anthracenediones such as mitoxantrone, substituted ureas such as hydroxyurea, methylhydrazine derivatives including N-methylhydrazine (MIH) and procarbazine, adrenal cortical suppressants such as mitotane (o,p-DDD) and aminoglutethimide; hormones and antagonists including adrenocortical steroid antagonists such as prednisone and equivalents, dexamethasone and aminoglutethimide; progestins such as Gemzar™ (gemcitabine), hydroxyprogesterone caproate, medroxyprogesterone acetate and megestrol acetate; estrogens such as diethylstilbestrol and ethinyl estradiol equivalents; antiestrogens such as tamoxifen; androgens including testosterone propionate and fluoxymesterone / equivalents; antiandrogens such as flutamide, gonadotropin releasing hormone analogs and leuprolide;and nonsteroidal antiandrogens such as flutamide. Therapies targeting epigenetic mechanisms include, but are not limited to, histone deacetylase inhibitors, demethylating agents (e.g., Vidaza), and transcriptional repression release (ATRA) therapy may also be combined with antigen binding proteins. In one embodiment, the chemotherapeutic agent is selected from the group consisting of taxanes (e.g., paclitaxel (Taxol), docetaxel (Taxotere), modified paclitaxel (e.g., Abraxane and Opacixo)), doxorubicin, sunitinib (Sutent), sorafenib (Nexavar), and other multikinase inhibitors, oxaliplatin, cisplatin and carboplatin, etoposide, gemcitabine, and vinblastine. In one embodiment, the chemotherapeutic agent is selected from the group consisting of taxanes (such as, for example, Taxol (paclitaxel), docetaxel (taxotere), modified paclitaxel (such as, for example, Abraxane and Opaxio). In one embodiment, the additional chemotherapeutic agent is selected from 5-fluorouracil (5-FU), leucovorin, irinotecan, or oxaliplatin. In one embodiment, the chemotherapeutic agent is 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI). In one embodiment, the chemotherapeutic agent is 5-fluorouracil and oxaliplatin (FOLFOX);
[0099] Specific examples of combination therapy with additional chemotherapeutic agents include, for example, therapy with a taxane (e.g., docetaxel or paclitaxel) or modified paclitaxel (e.g., Abraxane or Opacixo), doxorubicin), capecitabine, and / or bevacizumab (Avastin) for the treatment of breast cancer; therapy with carboplatin, oxaliplatin, cisplatin, paclitaxel, doxorubicin (or modified doxorubicin (Caelyx or Doxil)), or topotecan (Hycamtin) for the treatment of ovarian cancer; therapy with a multikinase inhibitor, MKI, (Sutent, Nexavar, or 706) and / or doxorubicin for the treatment of kidney cancer; therapy with oxaliplatin, cisplatin, and / or radiation for the treatment of squamous cell carcinoma; therapy with taxol and / or carboplatin for the treatment of lung cancer.
[0100] Thus, in one embodiment, the additional chemotherapeutic agent is selected from the group of taxanes (docetaxel or paclitaxel or modified paclitaxel (Abraxane or Opaxio), doxorubicin, capecitabine and / or bevacizumab for the treatment of breast cancer.
[0101] In one embodiment, the combination therapy of anti-TYRP1 / anti-CD3 antibody and TYRP1-specific antibody is in the absence of administration of a chemotherapeutic agent.
[0102] The present invention also includes methods for treating patients suffering from such diseases as described herein.
[0103] The present invention further provides methods for producing pharmaceutical compositions comprising an effective amount of the anti-TYRP1 / anti-CD3 antibodies of the invention described herein and TYRP1-specific antibodies of the invention described herein in association with a pharma- ceutically acceptable carrier, and the use of the anti-TYRP1 / anti-CD3 antibodies and TYRP1-specific antibodies of the invention described herein for such methods.
[0104] The present invention further provides the use of an anti-TYRP1 / anti-CD3 antibody according to the invention as described herein and a TYRP1 specific antibody according to the invention as described herein in an effective amount for the manufacture of a medicament, preferably together with a pharma- ceutically acceptable carrier, for the treatment of a patient suffering from cancer.
[0105] cell therapy In some embodiments, the immunotherapy is an activation immunotherapy. In some embodiments, the immunotherapy is provided as a treatment for cancer. In some embodiments, the immunotherapy comprises adoptive cell transfer.
[0106] In some embodiments, adoptive cell transfer involves administration of chimeric antigen receptor-expressing T cells (CAR T cells). One skilled in the art will appreciate that a CAR is a type of antigen-targeting receptor composed of an intracellular T cell signaling domain fused to an extracellular tumor-binding moiety, most commonly a single-chain variable fragment (scFv) from a monoclonal antibody.
[0107] CARs directly recognize cell surface antigens independent of MHC-mediated presentation, allowing the use of a single receptor construct specific for any given antigen in all patients. Early CARs fused the antigen recognition domain to the CD3 activation chain of the T cell receptor (TCR) complex. Although these first generation CARs elicited T cell effector functions in vitro, they were limited primarily by poor antitumor efficacy in vivo. Subsequent iterations of CARs included secondary costimulatory signals in parallel with CD3, and these included intracellular domains derived from CD28, or various TNF receptor family molecules such as 4-1BB (CD137) and OX40 (CD134). Furthermore, third generation receptors include two costimulatory signals in addition to CD3, most commonly those derived from CD28 and 4-1BB. Second and third generation CARs dramatically improved antitumor efficacy, in some cases causing complete remission in patients with advanced cancer. In one embodiment, a CAR T cell is an immunoresponsive cell that has been engineered to express a CAR, which becomes activated when the CAR binds to its antigen.
[0108] In one embodiment, CAR T cells are immunoresponsive cells that contain an antigen receptor, which is activated when the receptor binds to the antigen. In one embodiment, the CAR T cells used in the compositions and methods disclosed herein are first generation CAR T cells. In another embodiment, the CAR T cells used in the compositions and methods disclosed herein are second generation CAR T cells. In another embodiment, the CAR T cells used in the compositions and methods disclosed herein are third generation CAR T cells. In another embodiment, the CAR T cells used in the compositions and methods disclosed herein are fourth generation CAR T cells.
[0109] In some embodiments, adoptive cell transfer comprises administering T cell receptor (TCR) modified T cells. Those skilled in the art will understand that TCR modified T cells are produced by isolating T cells from tumor tissue and isolating their TCRa and TCRβ chains. These TCRa and TCRβ are then cloned and transfected into T cells isolated from peripheral blood, which then express TCRa and TCRβ from T cells that recognize the tumor.
[0110] In some embodiments, adoptive cell transfer comprises administering tumor infiltrating lymphocytes (TILs). In some embodiments, adoptive cell transfer comprises administering chimeric antigen receptor (CAR) modified NK cells. Those skilled in the art will understand that CAR modified NK cells include NK cells isolated from patients or commercially available NK cells engineered to express a CAR that recognizes a tumor-specific protein.
[0111] In some embodiments, the adoptive cell transfer comprises administering dendritic cells.
[0112] In some embodiments, the immunotherapy comprises administering a cancer vaccine. Those skilled in the art will appreciate that a cancer vaccine exposes the immune system to cancer-specific antigens and adjuvants. In some embodiments, the cancer vaccine is sipuleucel-T, GVAX, ADXS11-001, ADXS31-001, ADXS31-164, ALVAC-CEA vaccine, AC vaccine, talimogene laherparepvec, BiovaxID, Prostvac, CDX110, CDX1307, CDX1401, CimaVax-EGF, CV9104, DNDN, NeuVax, Ae-37, GRNVAC, tarmogens, GI-4000, GI-6207, GI-6301, ImPACT Therapy, IMA901, hepcortespenlisimut-L, Stimuvax, DCVax-L, DCVax-Direct, DCVax Prostate, CBLI, Cvac, RGSH4K, SCIB1, NCT01758328, and PVX-410.
[0113] The following examples, sequence listing and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.
[0114] Further embodiments: A further embodiment of the present invention is a novel TYRP1-specific antibody comprising a heavy chain variable domain VH of SEQ ID NO:1 and a light chain variable domain VL of SEQ ID NO:2.
[0115] In one embodiment, the TYRP1-specific antibody is of the human IgG1 subclass.
[0116] In another embodiment, the TYRP1-specific antibody comprises the polypeptide sequences of SEQ ID NO:13 and SEQ ID NO:14, or the polypeptide sequences of SEQ ID NO:15 and SEQ ID NO:16. EXAMPLES
[0117] Production and purification of muTYRP1 IgG Since the human IgG1 molecule elicits an immunogenic response in mice, the glycoengineered muIgG2a was used as a surrogate molecule for animal studies.
[0118] The antibody heavy and light chains were cloned on one plasmid under the control of a human CMV promoter-intron A-5'UTR cassette. Downstream of the genes is the BGH polyadenylation signal. The rat GnTIII gene was amplified by polymerase chain reaction (PCR) from a rat kidney cDNA library (BD Biosciences). The gene encoding ManII was amplified from human DNA using gene-specific primers. Both genes were combined with a chimeric MPSV promoter and subcloned into an expression vector. The vector was derived from pUC18 (Thermo Fisher Scientific) by inserting either a puromycin resistance gene or a hygromycin resistance gene and a scaffold attachment region (SAR) for enhanced expression.
[0119] CHO-K1SV cells were transfected with plasmids encoding the heavy and light chains of anti-TYRP1 muIgG2a and the enzymes N-acetylglucosaminyltransferase-III (GntIII) and mannosidase-II (ManII). Stable clones were selected and subjected to fed-batch culture in serum-free medium for up to 14 days to generate antibodies with modified glycosylation structures. Cell supernatants were harvested by centrifugation and subsequent filtration (0.2 μm filter), and antibodies were purified from the harvested supernatants by standard methods as described below.
[0120] Proteins were purified from filtered cell culture supernatants referring to standard protocols. Briefly, Fc-containing proteins were purified from cell culture supernatants by Protein A-affinity chromatography (equilibration buffer: 20 mM sodium citrate, 20 mM sodium phosphate, pH 7.5; elution buffer: 20 mM sodium citrate, 100 mM sodium chloride, 100 mM glycine, 0.01% Tween 20, pH 3.0). Elution was achieved at pH 3.0, immediately followed by pH neutralization of the samples. Proteins were concentrated by centrifugation (Millipore Amicon® ULTRA-15 (Art. Nr: UFC903096) and aggregated proteins were separated from monomeric proteins by size exclusion chromatography in 20 mM histidine, 140 mM sodium chloride, 0.01% Tween 20, pH 6.0.
[0121] The concentration of purified proteins was determined by measuring the absorbance at 280 nm using the mass attenuation coefficient calculated based on the amino acid sequence according to Pace et al., Protein Science, 1995, 4, 2411-1423. Protein purity and molecular weight were analyzed by CE-SDS in the presence and absence of reducing agents using a LabChip GXII or LabChip GX Touch (Perkin Elmer). Aggregate content was measured by HPLC chromatography at 25°C using an analytical size exclusion column (TSKgel G3000 SW XL or UP-SW 3000) equilibrated with running buffer (200 mM KH2PO4, 250 mM KCl pH 6.2, 0.02% NaN3). For determination of afucosylation levels, N-linked oligosaccharides were cleaved from purified IgG by incubation with 0.005 U PNGase F (QAbio, USA) and EndoH (QAbio, USA) in 20 mM Tris pH 8.0 for 16 h at 37° C. This gave free oligosaccharides that were analyzed by MALDI TOF mass spectrometry (Autoflex, Bruker Daltonics GmbH) in positive ion mode according to Papac et al. (1996) Anal. Chem., 68:3215-3223.
[0122] [Table 1]
[0123] [Table 2]
[0124] [Table 3]
[0125] Glycoengineered TYRP1 mouse IgG2a was purified by protein A and size-exclusion chromatography. Quality analysis of the purified material revealed a monomer content of 99% by analytical size-exclusion chromatography analysis (Table 1), a major product peak of 95% by non-reducing capillary electrophoresis (Table 2), and an afucosylation level of 52% by MALDI-TOF MS analysis (Table 3). Thus, glycoengineered TYRP1 mouse IgG2a can be produced in good quality with sufficient afucosylation levels to ensure increased ADCC.
[0126] In vivo efficacy of anti-TYRP1 / anti-CD3 bispecific antibodies alone and in combination with TYRP1-IgG antibody in syngeneic models of mouse tumor cell lines.
[0127] Anti-TYRP1 / anti-CD3 bispecific antibody (TYRP1-TCB) was tested for its anti-tumor efficacy in combination with TYRP1-IgG antibody in the B16-muFAP-Fluc metastatic melanoma syngeneic model. Mouse surrogates muTYRP1-TCB (SEQ ID NOs: 9, 10, 11, and 12) and muTYRP1-IgG (SEQ ID NOs: 15 and 16) were tested in Black 6 albino mice intravenously injected with the mouse melanoma B16-muFAP-Fluc double transfectant cell line.
[0128] B16 cells (mouse melanoma cells) were initially obtained from ATCC (Manassas, VA, USA) and deposited in the Roche-Glycart internal cell bank after expansion. The B16-muFAP-Fluc cell line was generated in-house by calcium transfection and subcloning techniques. B16-muFAP-Fluc was cultured in RPMI medium containing 10% FCS (Sigma), 200 μg / ml Zeocin, 0.75 μg / ml puromycin and 1% Glutamax. The cells were cultured at 37 °C, in a water-saturated atmosphere, 5% CO2. Passage 13 was used for transplantation. Cell viability was 94.3%. For each animal, 2 × 10 5 cells were injected intravenously (i.v.). Two hundred microliters of cell suspension (2 × 10 in RPMI medium) 5 B16-muFAP-Fluc cells) were injected into the tail vein.
[0129] Female Black6 albino mice (Charles Rivers, Lyon, France), aged 8-10 weeks at the start of the experiment, were maintained under specific pathogen-free conditions with a daily cycle of 12 h light / 12 h dark according to the restraint guidelines (GV-Solas; Ferrassa; Tiersch). The experimental study protocol was reviewed and approved by the local authorities (ZH225 / 2017). After arrival, the animals were maintained for one week to acclimate to the new environment and to be observed. Continuous health monitoring was performed at regular intervals.
[0130] Mice were dosed with 2 × 10 5 B16-muFAP-Fluc cells were injected intravenously, randomized, and weighed. Eighteen days after tumor cell injection, mice were injected iv once weekly with muTYRP1-TCB or muTYRP1-IgG alone for 4 weeks and compared with the combination of muTYRP1-TCB + muTYRP1-IgG.
[0131] All mice were injected intravenously with 200 μl of the appropriate solution. Mice in the vehicle group were injected with histidine buffer, and treatment groups were injected with 10 mg / kg muTYRP1-TCB and 20 mg / kg muTYRP1-IgG. Stock solutions were diluted with histidine buffer as needed to obtain the appropriate amount of immune complex per 200 μl.
[0132] [Table 4]
[0133] FIG. 1 shows that the combination of muTYRP1-TCB and muTYRP1-IgG mediated significantly superior efficacy in terms of improved median and overall survival compared to all other treatment groups and the vehicle group.
[0134] TIFF2024543257000005.tif251170TIFF2024543257000006.tif255170TIFF2024543257000007.tif139170
Claims
1. An anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1 specific antibody for use as a combination therapy in the prevention or treatment of metastasis, for use as a combination therapy in the treatment of cancer, comprising: an anti-TYRP1 / anti-CD3 bispecific antibody comprising a first antigen-binding portion that specifically binds to TYRP1 comprising a heavy chain variable domain VH of SEQ ID NO: 1 and a light chain variable domain VL of SEQ ID NO: 2, and a second antigen-binding portion that specifically binds to CD3 comprising a heavy chain variable domain VH of SEQ ID NO: 3 and a light chain variable domain VL of SEQ ID NO: 4; the second TYRP1-specific antibody comprises an antigen-binding portion that specifically binds to TYRP1; Anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1 specific antibody.
2. 1. Use of an anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1-specific antibody in the manufacture of a medicament for the treatment of cancer, comprising: an anti-TYRP1 / anti-CD3 bispecific antibody comprising a first antigen-binding portion that specifically binds to TYRP1 comprising a heavy chain variable domain VH of SEQ ID NO: 1 and a light chain variable domain VL of SEQ ID NO: 2, and a second antigen-binding portion that specifically binds to CD3 comprising a heavy chain variable domain VH of SEQ ID NO: 3 and a light chain variable domain VL of SEQ ID NO: 4; the second TYRP1-specific antibody comprises an antigen-binding portion that specifically binds to TYRP1; Use of an anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1-specific antibody.
3. 1. A method of treating cancer in an individual, comprising administering to said individual a therapeutically effective amount of an anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1-specific antibody; an anti-TYRP1 / anti-CD3 bispecific antibody comprising a first antigen-binding portion that specifically binds to TYRP1 comprising a heavy chain variable domain VH of SEQ ID NO: 1 and a light chain variable domain VL of SEQ ID NO: 2, and a second antigen-binding portion that specifically binds to CD3 comprising a heavy chain variable domain VH of SEQ ID NO: 3 and a light chain variable domain VL of SEQ ID NO: 4; The method, wherein the second TYRP1-specific antibody comprises an antigen-binding portion that specifically binds to TYRP1.
4. An anti-TYRP1 / anti-CD3 bispecific antibody combined with a second TYRP1-specific antibody for the use described in claim 1, the use described in claim 2, or the method described in claim 3, wherein the second antibody comprises a heavy chain variable domain VH of SEQ ID NO: 1 and a light chain variable domain VL of SEQ ID NO:
2.
5. The anti-TYRP1 / anti-CD3 bispecific antibody is a human IgG 1 Or human IgG 4 An anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1-specific antibody for use, use or method according to any one of claims 1 to 4, characterized in that it is an antibody of the subclass.
6. TYRP1-specific antibody is human IgG 1 An anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1-specific antibody for use, use or method according to any one of claims 1 to 5, characterized in that it is an antibody of the subclass.
7. An anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1-specific antibody for use, use or method according to any one of claims 1 to 6, characterized in that the anti-TYRP1 / anti-CD3 bispecific antibody has reduced or minimal effector function.
8. An anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1-specific antibody for use, use or method according to any one of claims 1 to 7, wherein the minimal effector function is due to an effector-less Fc mutation.
9. An anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1-specific antibody for use, use, or method according to claim 8, wherein the effector-less Fc mutation is L234A / L235A or L234A / L235A / P329G or N297A or D265A / N297A.
10. An anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1-specific antibody for use, use or method according to any one of claims 1 to 9, characterized in that the second TYRP1-specific antibody comprises an Fc domain with improved effector function, in particular improved ADCC function.
11. An anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1-specific antibody for use, use or method according to any one of claims 1 to 10, characterized in that the second TYRP1-specific antibody is afucosylated.
12. The anti-TYRP1 / anti-CD3 bispecific antibody i) the polypeptide sequence of SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8, ii) the polypeptide sequences of SEQ ID NO:5 and SEQ ID NO:6 and SEQ ID NO:7 and SEQ ID NO:8, or iii) the polypeptide sequences of SEQ ID NO:9 and SEQ ID NO:10 and SEQ ID NO:11 and SEQ ID NO:12 12. An anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1 specific antibody for use, use or method according to any one of claims 1 to 11 comprising:
13. The anti-TYRP1 / anti-CD3 bispecific antibody i) the polypeptide sequence of SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8, ii) the polypeptide sequences of SEQ ID NO:5 and SEQ ID NO:6 and SEQ ID NO:7 and SEQ ID NO:8, or iii) the polypeptide sequences of SEQ ID NO:9 and SEQ ID NO:10 and SEQ ID NO:11 and SEQ ID NO:12 and the second TYRP1 specific antibody comprises i) the polypeptide sequence of SEQ ID NO: 13 or SEQ ID NO: 14, or ii) the polypeptide sequences of SEQ ID NO: 13 and SEQ ID NO: 14, or iii) the polypeptide sequences of SEQ ID NO: 15 and SEQ ID NO: 16 13. An anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1 specific antibody for use, use or method according to any one of claims 1 to 12, comprising:
14. i) inhibiting tumor growth in tumors, and / or ii) improving median survival and / or overall survival of tumor-bearing subjects An anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1 specific antibody for use in The anti-TYRP1 / anti-CD3 bispecific antibody i) the polypeptide sequence of SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8, ii) the polypeptide sequences of SEQ ID NO:5 and SEQ ID NO:6 and SEQ ID NO:7 and SEQ ID NO:8, or iii) the polypeptide sequences of SEQ ID NO:9 and SEQ ID NO:10 and SEQ ID NO:11 and SEQ ID NO:12 Including, A second TYRP1-specific antibody, i) the polypeptide sequence of SEQ ID NO: 13 or SEQ ID NO: 14, or ii) the polypeptide sequences of SEQ ID NO: 13 and SEQ ID NO: 14, or iii) the polypeptide sequences of SEQ ID NO: 15 and SEQ ID NO: 16 An anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1 specific antibody comprising:
15. 15. An anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1 specific antibody for use, use or method according to any one of claims 1 to 14, wherein the cancer is selected from the group of breast cancer, lung cancer, colon cancer, ovarian cancer, melanoma cancer, bladder cancer, renal cancer, kidney cancer, liver cancer, head and neck cancer, colorectal cancer, melanoma, pancreatic cancer, gastric cancer, esophageal cancer, mesothelioma, prostate cancer, leukemia, lymphoma, myeloma.
16. An anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1-specific antibody for use, use or method according to any one of claims 1 to 15, wherein the patient is being treated with immunotherapy or is pre-treated with immunotherapy.
17. 17. An anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1-specific antibody for use, use, or method according to claim 16, wherein said immunotherapy comprises adoptive cell transfer, administration of a monoclonal antibody, administration of a cytokine, administration of a cancer vaccine, T cell induction therapy, or any combination thereof.
18. 18. The anti-TYRP1 / anti-CD3 bispecific antibody in combination with a second TYRP1 specific antibody for use, use or method according to claim 17, wherein adoptive cell transfer comprises administering chimeric antigen receptor expressing T cells (CAR T cells), T cell receptor (TCR) modified T cells, tumor infiltrating lymphocytes (TILs), chimeric antigen receptor (CAR) modified natural killer cells, T cell receptor (TCR) transduced cells, or dendritic cells, or any combination thereof.
